FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Keywords: 
FOSL1
Cholangiocarcinoma
Transcription factors
Genetics
Targeted therapies
Issue Date: 
2021
Publisher: 
Elsevier
ISSN: 
0168-8278
Note: 
This is an open access article under the CC BY-NC-ND license.
Citation: 
Vallejo-Blanco, A. (Adrián); Erice, O. (Oihane); Entrialgo-Cadierno, R. (Rodrigo); et al. "FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted". Journal of Hepatology. 75 (2), 2021, 363 - 376
Abstract
Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention.

Files in This Item:
Thumbnail
File
PIIS016882782100235X.pdf
Description
Size
2.89 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.